Subscribe
VBCC - March 2016, Vol 7, No 2 - Emerging Therapies
Corbin Davis

The investigational biosimilar (LA-EP2006) to the reference drug pegfilgrastim (Neulasta) has demonstrated similar results in patients with breast cancer who are receiving the regimen known as TAC (docetaxel, doxorubicin, and cyclophosphamide), according to data from the multicenter, randomized, double-blind PROTECT 2 trial.

C. Michael Jones, MD, FACP, the Jones Clinic, Germantown, TN, discussed the study results, which showed that the biosimilar was equivalent to peg­filgrastim in preventing severe neutropenia among patients who received neoadjuvant myelosuppressive chemotherapy.

“Biosimilar pegfilgrastim and the reference are similar, with no meaningful differences in efficacy, safety, or immunogenicity, and they are equivalent for all practical purposes in preventing severe neutropenia,” said Dr Jones. “We think that the biosimilar will facilitate access to supportive care by decreasing cost for these types of drugs and chemotherapy regimens where prophylaxis is necessary.”

PROTECT 2 is 1 of 2 pivotal clinical trials comparing LA-EP2006 with pegfilgrastim for the prevention of severe neutropenia in patients with breast cancer. Women receiving neoadjuvant TAC chemotherapy for breast cancer were randomized to receive a single 6-mg subcutaneous injection of LA-EP2006 or of pegfilgrastim on day 2 of each cycle.

Same Duration of Severe Neutropenia

Although a few patients did drop out in both study arms, the number of days patients had neutropenia was roughly the same.

“The differences are not statistically significant at this confidence level,” Dr Jones said. “LA-EP2006 and the reference are equivalent with respect to duration of severe neutropenia in cycle 1.”

Both drugs were also comparable in secondary efficacy parameters, including febrile episodes, depth of the absolute neutrophil count nadir and time to the absolute neutrophil count recovery in cycle 1, frequency of infection, and infection-related death.

Both drugs “were well tolerated, with comparable safety profiles,” said Dr Jones. “No treatment-related anti–pegfilgrastim-neutralizing antibodies were detected in either group, and in terms of treatment-related adverse events, the numbers are very similar between the groups.”

The biosimilar to pegfilgrastim could facilitate access to supportive care treatment for patients receiving myelosuppressive chemotherapy.

“Once-per-chemotherapy-cycle administration of pegfilgrastim could offer greater convenience, which may translate into better patient compliance and improved clinical outcomes compared to daily administration with filgrastim,” Dr Jones said.

Although he did not have access to specific pricing data, Dr Jones said that a 25% to 30% cost reduction can be expected, depending on Medicare reimbursement.

LA-EP2006 is pending approval by the FDA.

Related Items
Monoclonal Antibodies: The Future of Migraine Therapy
Corbin Davis
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Migraine Update
New Indications for Novel Antiepileptic Drugs May Offer Advantages for Patients with Seizures
Corbin Davis
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Epilepsy/Seizures
Ocrelizumab Promotes No Evidence of Disease Activity in Multiple Sclerosis
Chase Doyle
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Emerging Therapies
Alemtuzumab Most Cost-Effective Multiple Sclerosis Treatment for Achieving No Evidence of Disease Activity
Corbin Davis
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Value in Neurology
Emerging Disease-Modifying Therapies for Multiple Sclerosis
Chase Doyle
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Emerging Therapies
Dichlorphenamide Improves Outcomes in Periodic Paralysis
Chase Doyle
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Emerging Therapies
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Emerging Therapies
Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Cancer
Charles Bankhead
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Emerging Therapies
Inotuzumab Ozogamicin Shows Promise in Older Patients with Acute Lymphoblastic Leukemia
Phoebe Starr
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Emerging Therapies
Last modified: August 12, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology